HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.

@article{Heinmller2003HER2SI,
  title={HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin.},
  author={Petra Heinm{\"o}ller and Christof Gross and Kurt H Beyser and Claudia Schmidtgen and Gerd Maass and Michele Pedrocchi and Josef Rueschoff},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 14},
  pages={5238-43}
}
PURPOSE For the first time a large number (563) of non-small cell lung cancer (NSCLC) samples was used to compare three different technologies for the assessment of HER2 status. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were used for tumor tissue samples, and ELISA for serum samples. The results were compared with other tumor entities, mainly breast. EXPERIMENTAL DESIGN Samples (563) from patients suffering from primary advanced or metastatic NSCLC were… CONTINUE READING